Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Talazoparib tosylate is a novel and potent PARP1/2 (n IC50: 0.57 nM for PARP1).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 769 | 5日内发货 | ||
5 mg | ¥ 1,280 | 5日内发货 | ||
25 mg | ¥ 4,150 | 6-8周 | ||
50 mg | ¥ 5,400 | 6-8周 | ||
100 mg | ¥ 9,150 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,560 | 5日内发货 |
Talazoparib tosylate 的其他形式现货产品:
产品描述 | Talazoparib tosylate is a novel and potent PARP1/2 (n IC50: 0.57 nM for PARP1). |
靶点活性 | PARP1:0.57 nM |
体外活性 | Talazoparib inhibits PARP1 and -2 to a similar extent (Kis: 1.20 and 0.85 nM, respectively). Talazoparib induces nuclear γ-H2AX foci at concentrations as low as 100 pM. Talazoparib has no effect on PARG activity at concentrations up to 1 μM. Talazoparib binds to PARP1 with a dissociation constant of 0.29 nM. Talazoparib selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors. Talazoparib targets tumor cells with homologous recombination gene defects. Tumor models that are either BRCA1-deficient or BRCA2-deficient are profoundly sensitive to Talazoparib. [1]. |
体内活性 | Talazoparib is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxymethyl cellulose. Talazoparib (p.o.) elicits remarkable antitumor activity; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency are profoundly sensitive to oral Talazoparib treatment at well-tolerated doses in mice [1]. |
别名 | BMN 673ts |
分子量 | 552.55 |
分子式 | C26H22F2N6O4S |
CAS No. | 1373431-65-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 108 mg/mL (195.46 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8098 mL | 9.049 mL | 18.0979 mL | 45.2448 mL |
5 mM | 0.362 mL | 1.8098 mL | 3.6196 mL | 9.049 mL | |
10 mM | 0.181 mL | 0.9049 mL | 1.8098 mL | 4.5245 mL | |
20 mM | 0.0905 mL | 0.4524 mL | 0.9049 mL | 2.2622 mL | |
50 mM | 0.0362 mL | 0.181 mL | 0.362 mL | 0.9049 mL | |
100 mM | 0.0181 mL | 0.0905 mL | 0.181 mL | 0.4524 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Talazoparib tosylate 1373431-65-2 Chromatin/Epigenetic DNA Damage/DNA Repair PARP BMN 673ts Talazoparib Tosylate Inhibitor inhibitor inhibit